Valeria Cetoretta

Dr. Valeria Cetoretta

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Alfredo MaurielloAlfredo Mauriello
Alfredo Mauriello
ACAdriana Correra
Adriana Correra
AManna chiara Maratea
anna chiara Maratea
VCValeria Cetoretta
Valeria Cetoretta
GBGiovanni Benfari
Giovanni Benfari
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
Background: Immune checkpoint inhibitors (ICIs), such as anti-programmed death (PD)-1 and anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 agents, have revolutionized oncology but are associated with immune-related adverse events (irAEs). Among these, ICI-associated myocarditis (ICI-M) is a rare but life-threatening complication, with mortality rates ranging from 27% to 50%. Objective: This narrative review summarizes the pathogenesis, epidemiology, clinical presentation, diagnostic methods, and management strategies for ICI-induced myocarditis, specifically highlighting emerging biomarkers and immunosuppressive therapeutic approaches. Results and Discussion: ICI-M typically presents within the first 65 days of treatment and is significantly more frequent with combination therapies. Pathologically, it is characterized by myocyte necrosis and massive infiltration of cluster of differentiation (CD)4+ and CD8+ T-cells, often overlapping with myositis (irM/M). Diagnosis relies on a multimodal approach. Management requires immediate ICI cessation and initiation of high-dose corticosteroids as first-line therapy. For steroid-refractory cases, second-line options include mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIG), and emerging therapies like abatacept and ruxolitinib. Rechallenge with ICIs after high-grade ICI-M must be approached with extreme caution by the multidisciplinary team (MDT). Emerging biomarkers and omics techniques hold promise for earlier diagnosis and risk stratification. Conclusions: ICI-M is a rare yet highly lethal cardiac complication demanding high clinical vigilance and timely diagnosis. Management hinges on an aggressive multidisciplinary approach, aiming to minimize toxicity while balancing oncological efficacy.

14 November 2025 in Life
Verified
Journal Article
Open access
PDF file
Alfredo MaurielloAlfredo Mauriello
Alfredo Mauriello
ACAdriana Correra
Adriana Correra
AManna chiara Maratea
anna chiara Maratea
CFCeleste Fonderico
Celeste Fonderico
AAArianna Amata
Arianna Amata
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
The bidirectional link between cancer and cardiovascular disease presents a growing clinical challenge, often exacerbated by the cardiotoxic effects of many anti-cancer drugs. Simultaneously, the incidence of cardiovascular pathologies in cancer patients is on the rise. Recently, lipid-lowering drugs, particularly statins, have emerged not only as first-line cardiovascular drugs but also as potential agents with pleiotropic effects that could influence cancer progression and mitigate cardiotoxic side effects. We will analyze data from epidemiological studies, clinical trials, and laboratory research. This comprehensive review aims to examine and synthesize the current evidence regarding the use of lipid-lowering drugs in breast cancer patients, focusing on two main areas: their potential protective role in reducing the incidence of breast cancer and their impact on the prevention and management of treatment-induced cardiotoxicity.

Verified
Journal Article
Open access
PDF file
Alfredo MaurielloAlfredo Mauriello
Alfredo Mauriello
ACAdriana Correra
Adriana Correra
AManna chiara Maratea
anna chiara Maratea
VCValeria Cetoretta
Valeria Cetoretta
FGFrancesco Giallauria
Francesco Giallauria
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
Vasodilatory shock, primarily driven by sepsis, remains a leading cause of mortality in intensive care units (ICU), with mortality rates exceeding 90% in refractory cases. While norepinephrine is the first-line vasopressor, prolonged exposure to high doses of catecholamines is linked to severe adverse effects, including myocardial toxicity, arrhythmias, and immunodepression. Consequently, the concept of decatecholaminization, utilizing non-adrenergic vasopressors to reduce catecholamine burden, has emerged as a critical therapeutic strategy. This comprehensive review aims to define the current role of vasopressin and its analogues, terlipressin and selepressin, in managing patients with circulatory shock, evaluating their physiological rationale, clinical benefits, and adverse event profiles. The vasopressin system provides a multimodal approach to hemodynamic stability independent of α-adrenergic stimulation. Arginine vasopressin (AVP) acts on V1a receptors to induce vasoconstriction and improve glomerular filtration, and on V2 receptors for water reabsorption. Clinical trials indicate that while AVP may not reduce overall mortality, it significantly reduces the need for renal replacement therapy (RRT) and offers survival benefits in the less severe shock subgroup. Synthetic analogues like terlipressin offer a longer half-life but carry an increased risk of peripheral ischemia. Conversely, selepressin, a pure V1a agonist, was designed to mitigate fluid retention and edema, though recent trials have not yet demonstrated superior clinical outcomes over placebo. Modulation of the vasopressin system is a cornerstone of decatecholaminization in distributive and cardiogenic shock. Although a universal mortality benefit has not been established, these agents are crucial for protecting renal function, reducing catecholamine toxicity, and lowering the incidence of arrhythmias. Future strategies should focus on precision medicine, utilizing biomarkers like copeptin and artificial intelligence to optimize the timing and selection of multimodal vasopressor therapy.

10 February 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ACAdriana Correra
Adriana Correra
Alfredo MaurielloAlfredo Mauriello
Alfredo Mauriello
VCValeria Cetoretta
Valeria Cetoretta
AManna chiara Maratea
anna chiara Maratea
LRLucia Riegler
Lucia Riegler
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
Introduction: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use has ignited a debate regarding long-term safety, particularly concerning the risk of specific neoplasms and its ability to modulate cardiovascular health, not only as primary prevention but also as a potential agent to mitigate cardiotoxicity. Objectives: This narrative review aims to analyze the most recent evidence from clinical trials and post-marketing surveillance to evaluate the correlation between semaglutide use and the incidence of cancer, as well as the drug’s efficacy in reducing cardiotoxicity induced by anticancer therapies. Results and Discussion: While preclinical rodent models suggested a link to medullary thyroid carcinoma, human epidemiological data remain reassuring, though caution is advised in patients with genetic predisposition. Regarding pancreatic cancer, current meta-analyses do not confirm a significant increase in risk, suggesting that metabolic benefits outweigh potential concerns. Conclusions: Semaglutide is confirmed as a therapeutic tool with a highly favorable benefit–risk profile. While oncological monitoring must continue, the drug’s cardioprotective and anti-inflammatory properties open new frontiers not only in metabolic management but also in safeguarding cardiovascular integrity in complex clinical scenarios.

14 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ACAdriana Correra
Adriana Correra
VCValeria Cetoretta
Valeria Cetoretta
AManna chiara Maratea
anna chiara Maratea
SFSerena Ferrara
Serena Ferrara
ISIsabella Di Sarno
Isabella Di Sarno
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
Improved survival rates for paediatric cancer patients represent a major medical achievement, but they have simultaneously brought the long-term sequelae of oncological treatments into sharp focus. Cardiotoxicity stands out as one of the most serious complications, being the leading cause of non-relapse-related morbidity and mortality among childhood cancer survivors. This comprehensive review analyses the current landscape, highlighting the significant gap in evidence that hinders optimal care. This paper constitutes a comprehensive narrative and scoping review based on a critical analysis of current clinical guidelines, landmark studies, and consensus papers in paediatric cardio-oncology. Crucially, it assesses the heterogeneity and limitations of existing evidence regarding standardized surveillance protocols, primary prevention strategies, and acute/late-onset cardiovascular complication management. The review then identifies and critically discusses key areas for future research and clinical development. A critical gap in evidence persists in paediatric cardio-oncology, leading to significant variability in clinical practice and the underdiagnosis/undertreatment of cardiovascular risk factors in this vulnerable population. To bridge this gap, there is an urgent need for international collaborative research. The overarching goal is to transform paediatric cardio-oncology into a predictive and preventive speciality, ensuring that all childhood cancer survivors achieve not only extended life expectancy but also improved cardiovascular quality of life.

13 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
Alfredo MaurielloAlfredo Mauriello
Alfredo Mauriello
VCValeria Cetoretta
Valeria Cetoretta
CGCarmen Del Giudice
Carmen Del Giudice
ACAdriana Correra
Adriana Correra
AManna chiara Maratea
anna chiara Maratea
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
Cardiorenal syndrome (CRS) encompasses a spectrum of disorders in which acute or chronic dysfunction of the heart or the kidney induces dysfunction in the other. Although the five-subtype classification provides a useful conceptual framework, operational definitions remain heterogeneous and management requires an individualized approach. Traditionally attributed to reduced forward arterial perfusion, renal impairment in heart failure is increasingly associated with systemic venous congestion and renal venous hypertension, although most evidence is observational. At the humoral level, chronic activation of the renin–angiotensin–aldosterone system and the sympathetic nervous system sustains a cycle of oxidative stress, inflammation, and fibrosis. In this first part of a narrative review, we summarize these hemodynamic and humoral mechanisms and examine biomarkers that complement serum creatinine, including markers of filtration, tubular injury, and fibro-inflammatory activity, emphasizing that their interpretation depends on baseline renal function and congestion status. PubMed, Scopus, and Web of Science were searched up to September 2026. The available evidence is mainly observational and heterogeneous; these biomarkers appear complementary rather than substitutive, and their incremental clinical value requires prospective validation. Therapeutic strategies will be addressed in Part 2.